EGFR and central nervous system cancer: As a confirmation of the potential role of BOLD for molecular profiling and prognosis stratification, other authors [134] reported rOEF and R2′ (a BOLD-metric reflecting vascular oxygen-saturation) as being capable of discerning EGFR-amplification in gliomas (AUC 0.70 and 0.72, respectively), and both metrics were significant predictors of overall survival.